F
Fady I. Malik
Researcher at Gentofte Hospital
Publications - 153
Citations - 4504
Fady I. Malik is an academic researcher from Gentofte Hospital. The author has contributed to research in topics: Heart failure & Omecamtiv mecarbil. The author has an hindex of 29, co-authored 133 publications receiving 3371 citations. Previous affiliations of Fady I. Malik include Harvard University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Fady I. Malik,James J. Hartman,Kathleen A. Elias,Bradley P. Morgan,Hector P. Rodriguez,Katjuša Brejc,Robert L. Anderson,Sandra H. Sueoka,Kenneth Lee,Jeffrey T. Finer,Roman Sakowicz,Ramesh Baliga,David R. Cox,Marc Garard,Guillermo Godinez,Raja Kawas,Erica Kraynack,David Lenzi,Pu Ping Lu,Alexander Muci,Congrong Niu,Xiangping Qian,Daniel W. Pierce,Maria Pokrovskii,Ion Suehiro,Sheila Sylvester,Todd Tochimoto,Corey Valdez,Wenyue Wang,Tatsuo Katori,David A. Kass,You Tang Shen,Stephen F. Vatner,David J. Morgans +33 more
TL;DR: It is shown that omecamtiv mecarbil binds to the myosin catalytic domain and operates by an allosteric mechanism to increase the transition rate of myOSin into the strongly actin-bound force-generating state.
Journal ArticleDOI
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
John R. Teerlink,Rafael Diaz,G. Michael Felker,John J.V. McMurray,Marco Metra,Scott D. Solomon,Kirkwood F. Adams,Inder S. Anand,Alexandra Arias-Mendoza,Tor Biering-Sørensen,Michael Böhm,Diana Bonderman,John G.F. Cleland,John G.F. Cleland,Ramón Corbalán,María G. Crespo-Leiro,Ulf Dahlström,Luis E. Echeverría,James C. Fang,Gerasimos Filippatos,Cândida Fonseca,Eva Goncalvesova,Assen Goudev,Jonathan G. Howlett,David E. Lanfear,Jing Li,M. Lund,Peter S. Macdonald,Viacheslav Mareev,Shin-ichi Momomura,Eileen O'Meara,Alexander Parkhomenko,Piotr Ponikowski,Felix José Alvarez Ramires,Pranas Šerpytis,Karen Sliwa,Jindrich Spinar,Thomas M. Suter,János Tomcsányi,Hans Vandekerckhove,Dragos Vinereanu,Adriaan A. Voors,Mehmet Yilmaz,Faiez Zannad,Lucie Sharpsten,Jason C. Legg,Claire Varin,Narimon Honarpour,Siddique Abbasi,Fady I. Malik,Christopher E. Kurtz +50 more
TL;DR: Among patients with heart failure and a reduced ejection, patients who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo.
Journal ArticleDOI
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
John G.F. Cleland,John R. Teerlink,Roxy Senior,Evgeny M. Nifontov,John Murray,Chim C. Lang,Vitaly A. Tsyrlin,Barry H. Greenberg,Jamil Mayet,Darrel P. Francis,Tamaz Shaburishvili,Mark J. Monaghan,Mitchell T. Saltzberg,Ludwig Neyses,Scott M. Wasserman,Jacqueline H. Lee,Khalil G. Saikali,Cyril P. Clarke,Jonathan H. Goldman,Andrew A. Wolff,Fady I. Malik +20 more
TL;DR: Omecamtiv mecarbil improved cardiac function in patients with heart failure caused by left ventricular dysfunction and could be the first in class of a new therapeutic agent.
Journal ArticleDOI
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
John R. Teerlink,John R. Teerlink,G. Michael Felker,John J.V. McMurray,Scott D. Solomon,Kirkwood F. Adams,John G.F. Cleland,John G.F. Cleland,Justin A. Ezekowitz,Assen Goudev,Peter S. Macdonald,Marco Metra,Veselin Mitrovic,Piotr Ponikowski,Pranas Šerpytis,Jindrich Spinar,János Tomcsányi,Hans Vandekerckhove,Adriaan A. Voors,Maria Laura Monsalvo,James A. Johnston,Fady I. Malik,Narimon Honarpour +22 more
TL;DR: Omecamtiv mecarbil dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac function and decreased ventricular diameter, and the frequency of adverse clinical events did not differ between groups.
Journal ArticleDOI
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
John R. Teerlink,Cyril P. Clarke,Khalil G. Saikali,Jacqueline H. Lee,Michael M. Chen,Rafael D. Escandon,Lyndsey Elliott,Rachel Bee,Mohammad R. Habibzadeh,Jonathan H. Goldman,Nelson B. Schiller,Fady I. Malik,Andrew A. Wolff +12 more
TL;DR: First-in-man data show highly dose-dependent augmentation of left ventricular systolic function in response to omecamtiv mecarbil and support potential clinical use of the drug in patients with heart failure.